“What’s wrong”, “what’s wrong”, “is there any thunder”, Chongqing Zhifei Biological Products Co.Ltd(300122) ( Chongqing Zhifei Biological Products Co.Ltd(300122) ) the sharp decline on April 14 confused the company’s investors. On the morning of April 14, the leading vaccine maker Chongqing Zhifei Biological Products Co.Ltd(300122) staged a diving market with a market value of 100 billion yuan. The share price once fell by more than 18%. As of the noon closing of the day, the share price of the company closed down by 18.09%, with a total market value of 177.2 billion yuan and a half day market value of 39.1 billion yuan. On April 14, entries about HPV and Chongqing Zhifei Biological Products Co.Ltd(300122) also hit the microblog hot search list one after another.
The reporter of Beijing business daily learned that there is news on the market that “three doses of HPV vaccine can be given only one dose according to the official declaration of the who, and the protection rate is almost the same”, and this news is also regarded as the reason for the sharp decline of Chongqing Zhifei Biological Products Co.Ltd(300122) share price. On April 14, relevant personnel of Chongqing Zhifei Biological Products Co.Ltd(300122) secretary office said in an interview with the reporter of Beijing Business Daily that “the argument that three doses of HPV vaccine can only be given one dose has no clinical data support, and the company will actively respond.”
intraday share price fell by more than 18%
One hundred billion market value leader Chongqing Zhifei Biological Products Co.Ltd(300122) 4 on April 14, the share price plunged by more than 18%.
According to the trading market, on April 14, Chongqing Zhifei Biological Products Co.Ltd(300122) opened slightly higher. Shortly after the opening, the company’s share price turned green, and then the company dived under large orders. After the share price fell by more than 10%, it continued to decline, and once fell by more than 18%.
As of the noon closing of the day, Chongqing Zhifei Biological Products Co.Ltd(300122) shares were at 110.73 yuan / share, down 18.09%, and the market value fell below 200 billion yuan. As of the noon closing on April 14, the total market value of Chongqing Zhifei Biological Products Co.Ltd(300122) was 177.2 billion yuan, while as of the previous trading day, the total market value of the company was 216.3 billion yuan. After calculation, the total market value of the company evaporated 39.1 billion yuan in only half a day.
It is worth mentioning that behind the sharp drop in share price, Chongqing Zhifei Biological Products Co.Ltd(300122) there was no obvious bad news, and the sharp drop on April 14 also confused the company’s investors. On April 14, at the China stock market news stock bar, the market performance of Chongqing Zhifei Biological Products Co.Ltd(300122) also triggered a heated discussion among investors, among which some investors said “what happened”, “what happened”, “what caused the crash” and “is there any thunder”.
The reporter of Beijing business daily noted that in the market, the World Health Organization (who) announced on its official website that the who held an immunization strategy expert group (SAGE) meeting from April 4 to 7 to review the evidence of one dose of human tumor virus (HPV) vaccination. The expert group considered that only one dose of HPV vaccine can produce the same immune effect as 2-3 doses, and can effectively prevent cancer caused by HPV infection.
For the company’s share price plummeted and other issues, the reporter of Beijing Business Daily called Chongqing Zhifei Biological Products Co.Ltd(300122) secretary office on the morning of April 14 for an interview. The staff of the other party said that everything within the company was normal, and the sharp decline in share price was mainly due to the news released by the who, which did mention that three doses of HPV vaccine can only be given one shot, but did not give clinical data support. The company is also discussing and actively dealing with this situation.
It is understood that the HPV vaccines currently on the market in the world include the bivalent vaccine produced by GlaxoSmithKline in the UK, the tetravalent vaccine and the bivalent vaccine produced by methadone in the United States, and the bivalent vaccine produced by Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) in which methadone’s HPV vaccine jiadaxiu is managed by Chongqing Zhifei Biological Products Co.Ltd(300122) exclusively. Xu Xiaoheng, an investment and financing expert, told the Beijing Business Daily that as the exclusive agent of jiadaxiu, HPV vaccine has brought a lot of revenue to Chongqing Zhifei Biological Products Co.Ltd(300122) and “three doses of HPV vaccine can only be given one shot”. If it is true, it will certainly have a certain impact on the company’s performance, but whether this statement can be supported by data remains to be verified.
On April 14, Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) share price also plunged. As of midday closing, the company’s share price had fallen by the limit to 256.04 yuan / share, with a total market value of 155.4 billion yuan.
Chongqing Zhifei Biological Products Co.Ltd(300122) disclosed that the semi annual report of 2021 showed that in the composition of operating revenue, the company’s independent product vaccine generated a revenue of 6.037 billion yuan and a gross profit margin of 86.88%; Acting product – vaccine generated a revenue of 7.116 billion yuan and a gross profit margin of 33.99% Chongqing Zhifei Biological Products Co.Ltd(300122) relevant staff said in an interview with the reporter of Beijing Business Daily that the company’s agent products include four price, nine price HPV vaccine, five price rotavirus vaccine and so on, and there is no disclosure only about the revenue of HPV vaccine.
was recently given a buy rating by several securities companies
It should be noted that Chongqing Zhifei Biological Products Co.Ltd(300122) has recently been given a buy rating by a number of securities companies.
On March 31, Southwest Securities Co.Ltd(600369) released a research report, saying that Chongqing Zhifei Biological Products Co.Ltd(300122) was given a purchase rating of 138.28 yuan at the latest price. The reasons for the rating mainly include that the accelerated volume of HPV vaccine drives the rapid growth of the company’s traditional vaccine business; EC + micro card tuberculosis matrix mainly focuses on the student physical examination market, which is expected to increase rapidly.
In addition, Zhongtai Securities Co.Ltd(600918) also released a research report on March 31, saying that it maintained the purchase rating of Chongqing Zhifei Biological Products Co.Ltd(300122) at the latest price of 140.24 yuan. The reasons for the rating mainly included that the performance forecast exceeded expectations and the agency HPV vaccine performed well; The recombinant covid-19 vaccine has been approved for sequential vaccination in China and is expected to continue to increase its performance; The self-developed varieties have entered the cashing period, and the preventive micro card is expected to start rapid and large-scale production in 22 years.
Cinda securities, Huaxi Securities Co.Ltd(002926) , China Securities Co.Ltd(601066) securities and other securities companies also gave Chongqing Zhifei Biological Products Co.Ltd(300122) buy rating.
Statistics show that Chongqing Zhifei Biological Products Co.Ltd(300122) 2010 landed in the A-share market on September 28, 2010. It is a high-tech biological enterprise integrating vaccine and biological products research and development, production, sales, promotion, distribution, import and export. The company’s products include bacterial vaccine products, viral vaccine products and therapeutic biological products. By the end of 2020, a total of 10 products were on sale and one product was in emergency use.
In terms of performance, Chongqing Zhifei Biological Products Co.Ltd(300122) both the financial report in 2021 and the performance forecast in the first quarter of 2022 performed well.
On February 8 this year, Chongqing Zhifei Biological Products Co.Ltd(300122) disclosed the performance express of 2021. During the reporting period, the company achieved a total operating revenue of about 30.637 billion yuan, a year-on-year increase of 101.68%; The corresponding attributable net profit was about 10.197 billion yuan, a year-on-year increase of 208.88%.
As for the reasons for the significant increase in performance in 2021, Chongqing Zhifei Biological Products Co.Ltd(300122) said that during the reporting period, the company continued to focus on the business development objectives, increased R & D investment, pushed through the old and brought forth the new, continued to steadily improve the sales of independent products and agency products, and the main business income, net profit and other important financial indicators of the company increased significantly compared with the same period of last year.
On March 30, Chongqing Zhifei Biological Products Co.Ltd(300122) also disclosed the performance forecast for the first quarter of 2022. The company expects to realize the attributable net profit of about 1.783-1.97 billion yuan during the reporting period, an increase of 90% – 110% over the same period of the previous year. Economist song Qinghui told the Beijing Business Daily that when investors invest in the secondary market, they still need to look at the fundamentals of the company, pay attention to the market situation and make value investment.
